Monitoring of volatile and semi-volatile compounds was performed using gas chromatography (GC) coupled to high resolution electron ionization mass spectrometry, using both headspace and liquid injection modes on DB-624 and HP-5ms columns. A total of 1’300 reference compounds (n=400 analyzed on HP-5ms and n=900 on DB-624 columns), including n-alkanes (covering C5 to C30) as reference index markers, were analyzed and experimental linear retention indices (LRI) were determined. These reference compounds were randomly split into training and validation sets. LRI for all 1’300 reference compounds were predicted based upon computational Quantitative Structure-Property Relationship (QSPR) models using calculated 2D descriptors, and based on multiple approaches: PLS, Lasso regression, stepwise MLR, Genetic Evolution Algorithm predictor selection and Neural Networks, with PLS providing the fastest calculation and most accurate prediction level. Correlation coefficients for experimental versus predicted LRI values were calculated at 0.96 for DB-624 and 0.98 for HP-5ms for the training sets and at 0.94 and 0.95 for the validation sets, respectively. These models were then used to predict LRI values for several thousand reported metabolite compounds. The predicted LRI values can be used for column type selection as well as increased confidence level in unknown identification by means of the Mahalanobis distance.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.